Sorry, you need to enable JavaScript to visit this website.

WHY Galderma Pioneering science

The world’s most diverse range of fillers

The complementary NASHA™ and OBT™* technologies create fillers with unique properties to offer an extensive range of effects.1,2,3,4 

Two technologies that provide individualized and natural looking results

Most patients desire natural results that improve their appearance while preserving their own unique identity. To fulfill patients’ individual needs and desires, Galderma has developed two different and complementary technologies for the stabilization of hyaluronic acid molecules – NASHA™ and OBT™. By also using different particle sizes of the stabilized gel, a range of fillers with distinct and unique properties has been created:

– From firm to flexible gel textures4,5,6
– From moderate to high lifting capacity

The NASHA technology is designed for lifting and precision, whereas the OBT technology is designed for contouring and expression. 

Understanding NASHA and OBT technologies will help you to understand how the different fillers behave in the skin and how to create the optimal and most natural looking result for your patients. 

A doctor sitting with a satisfied patient

NASHA™ – minimally modified gels for lifting and precision

NASHA gel is relatively firm, and the HA has been minimally modified so as not to be recognized by the body as foreign. NASHA gels rely largely on the natural entanglement of hyaluronic acid strands for cross-linking. A relatively small number of additional cross-links are added to slow degradation in the body and prolong the effect. NASHA features targeted product integration into the tissue with a pronounced lifting capacity, which enables projection and definition.

NASHA is used for:

  • Projection and definition
  • Patients where a firmer product is preferred
  • Enhancing the cheeks and filling wrinkles and folds8,9 
  • Nose, chin, and jawline when precision is needed10 

The NASHA technology is used in:
Restylane Lyft™ – with a larger gel particle size to deliver lift, fill and volume
Restylane™ – with a mid-sized particle to fill wrinkles and lines
Restylane Skinboosters™ – with a smaller gel particle size to deliver hydration and moisture deep inside the skin, with a minimal lifting effect

Sat, 01/25/2020 - 21:47
Scientist pioneering new aesthetic treatments
Scientist pioneering new aesthetic treatments

OBT™ – flexible gels for contouring and expression

OBT technology is characterized by soft and flexible gels that enable you to create contouring and volume in the mid-face. 

OBT gels can be used for patients with thinner tissue coverage, where a softer product is preferred. They can also be used for dynamic treatment areas that require tissue support while maintaining animation, such as lips, nasolabial folds, and marionette lines. OBT creates a diverse range of natural effects by offering:11 

  • Varying degrees of cross-linking
  • Softer and more flexible gels
  • Distributed product integration in the tissue for contouring and volume

OBT technology is used in:

Restylane Volyme™, Restylane Defyne™ and Restylane Kysse™ – with a larger gel particle size to provide volume and add definition. Fewer cross-links provides a softer gel (such as Volyme), while more cross-links between HA molecules result in a firmer gel (such as Kysse).

Restylane Fynesse™ and Restylane Refyne™ – with a smaller gel particle size, provide a lower lifting capacity to target superficial wrinkles and fine lines. A relatively high number of cross-links result in a firmer gel.

Tue, 01/26/2021 - 09:17

Restylane was the first-ever stabilized non-animal HA filler12

Proven safety and efficacy with over 60 randomized controlled trials13

Cited in 320 scientific publications14

Experts explain why they choose Galderma's pioneering science?


  1. Data on file (MA-33939).
  2. Öhrlund A. Poster presented at AMWC 2019.
  3. Philipp-Dormston WG et al. Dermatol Surg 2018;44(6):826–832
  4. Data on file (MA-34675)
  5. Öhrlund A. Poster presented at AMWC 2019.
  6. Narins RS et al. Dermatol Surg 2011;37:644–650.
  7. Data on file (MA-33947)
  8. Weiss RA et al. Dermatol Surg 2016;42:699–709.
  9. Narins RS et al. Dermatol Surg 2011;37:644–650.
  10. Data on file (MA-39364)
  11. Segura S et al. J Drugs Dermatol 2012;11(1 Suppl:s5–8).; Tezel A and Fredrickson GH. J Cosmet Laser Ther 2008;10:35–42.; Data on File (MA-33947).
  12. Data on file (MA-39680) 
  13. Pubmed search for ‘Restylane’ Available at Accessed July 2019.
  14. Pubmed search for ‘Restylane’ Available at Accessed July 2019.